The Food Professor Podcast welcomes Ransom Hawley, CEO of Caddle, for a compelling deep dive into how GLP-1 weight-loss drugs are transforming Canadian food consumption. Hawley shares exclusive insights revealing a surge in GLP-1 usage, a shift from diabetes management to weight loss, and dramatic declines in snacking, alcohol and sugary beverages. Meanwhile, demand for protein-rich and functional foods is rising fast. Michael and Sylvain explore why this trend may become the most disruptive force shaping food retail and restaurants in the decade ahead.
This episode of The Food Professor Podcast takes a deep dive into one of the most powerful forces now reshaping the food industry: the rapid rise of GLP-1 weight-loss drugs such as Ozempic and Wegovy. Hosts Michael LeBlanc and Dr. Sylvain Charlebois begin with a run-through of current food and retail headlines, including controversy at Campbell Soup, conversations around AI adoption and innovation in the food sector, and early teasers from the 2026 Canada Food Price Report. These stories set the stage for this week’s feature discussion: how GLP-1 medications are altering what consumers eat, where they shop, and which products they choose.
The heart of the episode features an in-depth interview with Ransom Hawley, Founder and CEO of Caddle, a Canadian mobile-first consumer insights platform with access to real-time behavioural data. Hawley shares new Canadian research showing GLP-1 household usage has jumped from 10% to 14% over two years, a dramatic 40% increase. Equally important is the shift in why people are taking these drugs: where most users initially relied on them to manage type-2 diabetes, an increasing number now use them primarily for weight loss. That consumer pivot mirrors rapid adoption trends in the United States and offers important clues about what’s coming next for Canadian retailers, manufacturers and restaurants.
Hawley reveals that GLP-1 users report eating less, losing weight, buying fewer groceries, and reducing restaurant visits. Consumption of alcohol, sugary beverages and impulse-driven snack foods is falling, while protein-rich foods, functional beverages and satiety-oriented products are gaining momentum. Categories seeing the steepest declines include bakery goods, packaged cookies, chocolates, soft drinks and sweet snacks—all long-time staples of convenience-driven food consumption. This suggests a structural shift, not a temporary fad.
The conversation expands to consider the broader implications. As GLP-1 usage rises, brands face new challenges and opportunities: How should they reformulate products for consumers who eat less? Should retailers redesign planograms to reflect category shrinkage? Will foodservice operators pivot toward protein-forward meals, smoothies and portion-smart menu strategies? As the hosts discuss, this is the first time since COVID-era lockdowns that such a large segment of the population is simultaneously changing eating behaviours, and its ripple effects will reshape category strategies, promotional plans, and innovation pipelines.
By the end of the episode, one thing is clear: GLP-1 drugs are not just a pharmaceutical phenomenon—they are transforming food culture, retail economics, and consumer expectations. Retailers and brands that ignore this shift risk falling behind; those who understand it may unlock a once-in-a-generation competitive advantage.